Muhammad Badar

Dr. Muhammad Badar


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
MAMuhammad Usman Akbar
Muhammad Usman Akbar
Saadullah KhattakSaadullah Khattak
Saadullah Khattak
MKMalik Ihsanullah Khan
Malik Ihsanullah Khan
USUmair Ali Khan Saddozai
Umair Ali Khan Saddozai
NANemat Ali
Nemat Ali
MBMuhammad Badar
Muhammad Badar
Cancer has remained one of the leading causes of death worldwide, with a lack of effective treatment. The intrinsic shortcomings of conventional therapeutics regarding tumor specificity and non-specific toxicity prompt us to look for alternative therapeutics to mitigate these limitations. In this regard, we developed multifunctional bimetallic (FeCo) bi-MIL-88B-FC MOFs modified with folic acid—conjugated chitosan (FC) as drug delivery systems (DDS) for targeted delivery of 5-Fluorouracil (5-FU). The bi-MIL-88B nanocarriers were characterized through various techniques, including powder X-ray diffraction, scanning electron microscopy, energy-dispersive X-ray, thermogravimetric analysis, and Fourier transform infrared spectroscopy. Interestingly, 5-FU@bi-MIL-88B-FC showed slower release of 5-FU due to a gated effect phenomenon endowed by FC surface coating compared to un-modified 5-FU@bi-MIL-88B. The pH-responsive drug release was observed, with 58% of the loaded 5-FU released in cancer cells mimicking pH (5.2) compared to only 24.9% released under physiological pH (5.4). The in vitro cytotoxicity and cellular internalization experiments revealed the superiority of 5-FU@bi-MIL-88B-FC as a highly potent targeted DDS against folate receptor (FR) positive SW480 cancer cells. Moreover, due to the presence of Fe and Co in the structure, bi-MIL-88B exhibited peroxidase-like activity for chemodynamic therapy. Based on the results, 5-FU@bi-MIL-88B-FC could serve as promising candidate for smart DDS by sustained drug release and selective targeting.

30 August 2022 in ACS Omega
Verified
Journal Article
Open access
MAMuhammad usman Akbar
Muhammad usman Akbar
MBMuhammad Badar
Muhammad Badar
MZMuhammad Zaheer
Muhammad Zaheer
Along with the increasing incidence of cancer and drawbacks of traditional drug delivery systems (DDSs), developing novel nanocarriers for sustained targeted-drug release has become urgent. In this regard, metal-organic frameworks (MOFs) have emerged as potential candidates due to their structural flexibility, defined porosity, lower toxicity, and biodegradability. Herein, a FeMn-based ferromagnetic MOF was synthesized from a preassembled Fe2Mn(μ3-O) cluster. The introduction of the Mn provided the ferromagnetic character to FeMn-MIL-88B. 5-Fluoruracil (5-FU) was encapsulated as a model drug in the MOFs, and its pH and H2S dual-stimuli responsive controlled release was realized. FeMn-MIL-88B presented a higher 5-FU loading capacity of 43.8 wt % and rapid drug release behavior in a tumor microenvironment (TME) simulated medium. The carriers can rapidly release loaded drug of 70% and 26% in PBS solution (pH = 5.4) and NaHS solution (500 μM) within 24 h. The application of mathematical release models indicated 5-FU release from carriers can be precisely fitted to the first-order, second-order, and Higuchi models of release. Moreover, the cytotoxicity profile of the carrier against human embryonic kidney cells (HEK293T) suggests no adverse effects up to 100 μg/mL. The lesser toxic effect on cell viability can be attributed to the low toxicity values [LD50 (Fe) = 30 g·kg-1, (Mn) = 1.5 g·kg-1, and (terephthalic acid) = 5 g·kg-1] of the MOFs structural components. Together with dual-stimuli responsiveness, ferromagnetic nature, and low toxicity, FeMn-MIL-88B MOFs can emerge as promising carriers for drug delivery applications.

12 October 2023 in Materials Advances
Verified
Journal Article
Open access
PDF file
MAMuhammad usman Akbar
Muhammad usman Akbar
AAArslan Akbar
Arslan Akbar
USUmair Ali Khan Saddozai
Umair Ali Khan Saddozai
MKMalik Ihsan Ullah Khan
Malik Ihsan Ullah Khan
MZMuhammad Zaheer
Muhammad Zaheer
MBMuhammad Badar
Muhammad Badar
By combining two different ligands and metals, MOFs can be fine-tuned for effective encapsulation and delivery of two anticancer drugs.

19 September 2022 in Cells
Verified
Journal Article
Open access
PDF file
USUmair Ali Khan Saddozai
Umair Ali Khan Saddozai
FWFengling Wang
Fengling Wang
Saadullah KhattakSaadullah Khattak
Saadullah Khattak
MAMuhammad usman Akbar
Muhammad usman Akbar
MBMuhammad Badar
Muhammad Badar
XGXiangqian Guo
Xiangqian Guo
Malignant pleural mesothelioma (MPM) is a fatal disease of respiratory system. Despite the availability of invasive biomarkers with promising results, there are still significant diagnostic and therapeutic challenges in the treatment of MPM. One of three main mesothelioma cell types, epithelioid mesothelioma makes up approximately 70% of all mesothelioma cases. Different observational findings are under process, but the molecular heterogeneity and pathogenesis of epithelioid malignant pleural mesothelioma (eMPM) are still not well understood. Through molecular analysis, expression profiling data were used to determine the possibility and optimal number of eMPM molecular subtypes. Next, clinicopathological characteristics and different molecular pathways of each subtype were analyzed to prospect the clinical applications and advanced mechanisms of eMPM. In this study, we identified two distinct epithelioid malignant pleural mesothelioma subtypes with distinct gene expression patterns. Subtype I eMPMs were involved in steroid hormone biosynthesis, porphyrin and chlorophyll metabolism, and drug metabolism, while subtype II eMPMs were involved in rational metabolism, tyrosine metabolism, and chemical carcinogenesis pathways. Additionally, we identified potential subtype-specific therapeutic targets, including CCNE1, EPHA3, RNF43, ROS1, and RSPO2 for subtype I and CDKN2A and RET for subtype II. Considering the need for potent diagnostic and therapeutic biomarkers for eMPM, we are anticipating that our findings will help both in exploring underlying mechanisms in the development of eMPM and in designing targeted therapy for eMPM.

2 May 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
HHHamna Batool Hashmi
Hamna Batool Hashmi
MFMuhammad Asad Farooq
Muhammad Asad Farooq
MKMuhammad Hashim Khan
Muhammad Hashim Khan
AAAbdulrahman Alshammari
Abdulrahman Alshammari
AAAlanoud T. Aljasham
Alanoud T. Aljasham
Mohammad MubarakMohammad Mubarak
Mohammad Mubarak
Methicillin-resistant Staphylococcus aureus (MRSA) is among the leading causes of nosocomial infections and forms biofilms, which are difficult to eradicate because of their increasing resistance to antimicrobial agents. This is especially true for pre-existing biofilms. The current study focused on evaluating the efficacy of three β-lactam drugs, meropenem, piperacillin, and tazobactam, alone and in combination against the MRSA biofilms. When used individually, none of the drugs exhibited significant antibacterial activity against MRSA in a planktonic state. At the same time, the combination of meropenem, piperacillin, and tazobactam showed a 41.7 and 41.3% reduction in planktonic bacterial cell growth, respectively. These drugs were further assessed for biofilm inhibition and removal. The combination of meropenem, piperacillin, and tazobactam caused 44.3% biofilm inhibition, while the rest of the combinations did not show any significant effects. Results also revealed that piperacillin and tazobactam exhibited the best synergy against the pre-formed biofilm of MRSA, with 46% removal. However, adding meropenem to the piperacillin and tazobactam combination showed a slightly reduced activity towards the pre-formed biofilm of MRSA and removed 38.7% of it. Although the mechanism of synergism is not fully understood, our findings suggest that these three β-lactam drugs can be used in combination as very effective therapeutic agents for the treatment of pre-existing MRSA biofilms. The in vivo experiments on the antibiofilm activity of these drugs will pave the way for applying such synergistic combinations to clinics.

23 August 2024 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
SRSheikh Abdur Rashid
Sheikh Abdur Rashid
FNFaiza Naseem
Faiza Naseem
PSPervaiz Akhtar Shah
Pervaiz Akhtar Shah
HHHamna Batool Hashmi
Hamna Batool Hashmi
MMMudassar Mazher
Mudassar Mazher
MBMuhammad Badar
Muhammad Badar